An official website of the United States government
Pfizer withdrew voxelotor (Oxbryta), a medication for sickle cell disease, from the market in September 2024 due to its benefits no longer outweighing the risks for the approved patient population.
In September 2024, Pfizer withdrew voxelotor (also called Oxbryta) from the market. The medicine was used to prevent sickling in red blood cells. Pfizer said the benefits of using voxelotor do not outweigh the risks in the approved sickle cell population.
En sept. 2024, Pfizer retiro voxelotor (Oxbryta) del mercado. Una medicina usada para prevenir la formación de células falciformes. Pfizer dijo que los beneficios de usar voxelotor no son mayores que los riesgos en la población en la que fue aprobada.
disease_condition
Pfizer withdrew voxelotor (Oxbryta) in September 2024 because its benefits for sickle cell patients no longer outweigh the risks.